iSpecimen (NASDAQ:ISPC) Stock to Reverse Split on Tuesday, November 24th

iSpecimen Inc. (NASDAQ:ISPC – Free Report) shares are scheduled to reverse split before the market opens on Tuesday, November 24th. The 1-6 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, November 23rd.

iSpecimen Stock Down 1.0%

NASDAQ:ISPC opened at $0.53 on Friday. The company has a market capitalization of $1.33 million, a PE ratio of -0.01 and a beta of 1.54. iSpecimen has a 52-week low of $0.47 and a 52-week high of $27.44. The stock’s 50 day moving average price is $0.99 and its 200 day moving average price is $3.99.

iSpecimen (NASDAQ:ISPC – Get Free Report) last released its quarterly earnings results on Tuesday, November 17th. The company reported ($1.03) EPS for the quarter. The firm had revenue of $0.24 million for the quarter. iSpecimen had a negative return on equity of 447.19% and a negative net margin of 1,796.52%.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of iSpecimen from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, October 29th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company has an average rating of “Sell”.

Check Out Our Latest Research Report on ISPC

About iSpecimen

(Get Free Report)

iSpecimen, Inc. operates an online marketplace that connects life-science researchers with hospitals, laboratories, biobanks and other providers of human biospecimens. Its platform is designed to help researchers find and request samples for medical and scientific research. Through its iSpecimen Marketplace, the company facilitates access to materials such as blood, tissue and other human specimens, along with associated data when available. It also supports the coordination of specimen sourcing and fulfillment between research organizations and providers.

Featured Articles

Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.